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BV Relapse HR vs. BSC
0.5 0.6 0.7 0.8
Life Years Gained 3.8 2.9 2.1 1.3
QALYs Gained 4.1 3.1 2.3 1.4
Additional Cost $155,000 $162,000 $169,000 $176,000
Cost Per Life Year
$6#Gained
$40,789 $55,862 $80,476 $135,384
Cost Per QALY Gained $37,804 $52,258 $73,478 $125,714
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S146Conclusion: GM-CSF use after AHPCT for MM may be
associated with a higher risk of ES and longer time to
neutrophil recovery as compared to G-CSF. Our observations
should prompt further investigation.
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: Hodgkin Lymphoma (HL) that relapses
following autologous stem cell transplant (ASCT) is costly to
treat and carries an unfavorable prognosis. Brentuximab
vedotin (BV), a novel agent to reduce the risk of relapse
following ASCT, offers the potential to be both effective and
cost-effective. Anticipating the results of the AETHERA trial,
we constructed a decision model to estimate the cost-effec-
tiveness of BV vs. best supportive care (BSC) for adult HL
patients at high risk of relapse following ASCT.
Methods, Intervention, & Analysis: The model is con-
structed as a Markov process, taking the U.S. health insurer
perspective and a lifetime horizon. Following ASCT, high-risk
HL patients are treatedwith BV or BSC alone. After treatment,
patients enter one of 5 health states: remission; relapse/
salvage therapy; relapse/palliative care; 2nd remission;death. Transition probabilities were based on published re-
ports, bone marrow transplant registry data, and life tables.
Drug cost was ASP + 6%. Costs are based on 2013 Medicare
reimbursements.
Findings & Interpretation: In the base case (HR 0.667 for BV
vs. BSC), total life years, QALYs, and costs were 16.7, 13.4, and
$308,000 for the BV strategy vs. 14.3, 10.9, and $140,000 for
the BSC strategy. The cost per life year gained and cost per
QALY gained for BV vs. BSC were $70,000 and $67,200,
respectively. Economic outcomes across a range of hazard
ratios (HR) for BV vs BSC are as follows:
Results were most sensitive to: (a) efﬁcacy of BV (relapse
HR), (b) monthly drug cost, and (3) cycles of treatment. In the
base case, the likelihood of BV being cost-effective was 92.6%
at a willingness to pay threshold of $100,000 per QALY.
Discussion & Implications: BV has the potential to be cost-
effective in HL patients at risk for relapse following ASCT. The
AETHERA trial will provide more precise estimates of the
cost-effectiveness of this therapy.
